Standard specimen reporting guidelines from the College of American Pathologists (CAP; 2021) recommend biomarker analysis on diagnostic biopsies, including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), for invasive breast carcinomas [1]. Here, PGR is linked to invasive breast carcinoma.